Lots of sad stories coming out. Truly sorry to hear of your...

Lots of sad stories coming out. Truly sorry to hear of your losses.

I hope for most of you tis was just 10% or so of your portfolio, rather than the many eggs in one basket etc.

If one bought at 40c and you are not averaging down, then it's hard to get your money back. But if you average down, and in a big way as the share price is so low at the moment, one can be back in profit within a few cents.

As I said before, one needs to look forward. I'm sure there were many neu share holders who lost bucket loads and walked away. Averaging down at 1.3c could have brought them into profit and beyond in no time. With neu I was down about $20k, and ended up over many many times that.

So why invest in ftt now?

Well those snippets of trial data we have had:

In the benchmark study 41% of patients fully healed. In our current one it's currently 53%.

If we assume in our study that the placebo's third is similar to the benchmark study, then the two thirds on our drug have a full healing rate of 60%.

60% compared to 41% is nearly a 50% improvement over the benchmark, which is a hugely statistically significant benefit.

Then there's the 50% healing data showing a possible 300% improvement.

And less pain has been reported by subjects.

And in our trial there is a two weeks screening to weed at those who will easily heal on standard treatment, which was not the case with the benchmark study, so our placebo is likely to perform poorer than the benchmark study.

We only need to show a 10% improvement over the placebo for trial success, but we might be looking at a 50% or 100% improvement or more.

A success fda approved phase 2 trial with strong positive results is easily enough to satisfy European and other territories approval.

A strong result also de-risks the phase 3, which is required for US approval.

The company is already in dialogue with potential partners, and a good clinical trial result should easily attract a partnership or takeover. Our product is very commercial, as it saves health authorities lots of money.

cheers